Galmed Pharmaceuticals Ltd. (GLMD)

Market Cap	1.71M
Revenue (ttm)	n/a
Net Income (ttm)	-6.36M
Shares Out	6.01M
EPS (ttm)	-2.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,594
Open	0.294
Previous Close	0.288
Day's Range	0.280 - 0.297
52-Week Range	0.260 - 5.470
Beta	0.80
Analysts	Strong Buy
Price Target	4.00 (+1,302.03%)
Earnings Date	Aug 7, 2024

About GLMD

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 13, 2014
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: GLMD

Analyst Forecast

According to one analyst, the rating for GLMD stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target

$4.0

(1,302.03% upside)

Analyst Consensus: Strong Buy